Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 87

Results For "NAL"

6625 News Found

Bayer wins Japan nod for finerenone in broad heart failure population
Drug Approval | December 23, 2025

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients


FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
Drug Approval | December 23, 2025

FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer

This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care


SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
Hospitals | December 23, 2025

SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient

TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.


FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
Drug Approval | December 23, 2025

FDA go-ahead to Roche’s one-minute follicular lymphoma therapy

Full approval will depend on verification of clinical benefit in a confirmatory trial


Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
News | December 23, 2025

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial

According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million


Zydus Partners with Bioeq for US commercialisation rights for Nufymco
News | December 23, 2025

Zydus Partners with Bioeq for US commercialisation rights for Nufymco

NUFYMCO BLA has been approved by the USFDA


Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
Clinical Trials | December 22, 2025

Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial

The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile


Sai Life Sciences unveils 2024–25 sustainability report
Sustainability | December 22, 2025

Sai Life Sciences unveils 2024–25 sustainability report

The company also reported significant progress toward its internally defined Sustainable Development Goals


Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million
Biopharma | December 22, 2025

Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million

Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs